Evidence map›Paper›PMID 41222729›Full record

ReviewMolecular neurobiology2025

The Synergistic Role of ApoE4 and GSK3β in Alzheimer's Disease: Pathological Mechanisms and Therapeutic Implications.

Qianwei Li, Yinghui Shang, Han-Chang Huang, Xueling Dai, Fengxue Lao

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qianwei LiCollege of Biochemical Engineering, Beijing Union University, Beijing, 100023, China.
Yinghui ShangCollege of Biochemical Engineering, Beijing Union University, Beijing, 100023, China.
Han-Chang HuangCollege of Biochemical Engineering, Beijing Union University, Beijing, 100023, China.
Xueling DaiCollege of Biochemical Engineering, Beijing Union University, Beijing, 100023, China.
Fengxue LaoCollege of Biochemical Engineering, Beijing Union University, Beijing, 100023, China. bytfengxue@buu.edu.cn.ORCID http://orcid.org/0000-0002-5997-7137

Funding

Beijing Union University ZKZD202304
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by significant cognitive decline. Glycogen synthase kinase-3β (GSK3β), a key regulator in the pathological process of AD, exacerbates neuronal damage by phosphorylating tau proteins and promoting Aβ production. The activity of GSK3β is modulated by multiple signaling cascades, including the PI3K/AKT and Wnt/β-catenin transduction pathways. Furthermore, Apolipoprotein E ε4 (ApoE4) has been identified as a major genetic risk factor for increased susceptibility to AD. ApoE4 aggravates lipid metabolism disorders by interfering with LRP1 receptor function, inhibiting insulin signaling, and promoting the release of inflammatory factors (IL-6, TNF-α) and GSK3β. Specifically, ApoE4 may intensify the pathological process of AD by interacting with GSK3β, altering the balance of lipid metabolism in the body, regulating GSK3β activity, and modulating neuroinflammatory responses. This article systematically reviews the synergistic mechanisms of ApoE4 and GSK3β in AD and provides a new theoretical basis and potential intervention strategies for early diagnosis and targeted therapy of AD.

Indexed as

Alzheimer DiseaseApolipoprotein E4Glycogen Synthase Kinase 3 betaAnimalsHumansLipid MetabolismSignal TransductionApolipoprotein E4Glycogen Synthase Kinase 3 betaAlzheimer’s diseaseApoE4GSK3βLipid metabolismPI3K/AKTWnt/β-catenin

Identifiers

PMID41222729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.